Lianna J Marks
Overview
Explore the profile of Lianna J Marks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
126
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blosser C, Marks L, Dharnidharka V
Am J Transplant
. 2025 Mar;
PMID: 40064296
No abstract available.
2.
Marks L, Wu Y, McCarten K, Renfro L, Pei Q, Kelly K, et al.
Pediatr Blood Cancer
. 2025 Feb;
:e31606.
PMID: 39953678
A better understanding of positron emission tomography (PET) response in nodular lymphocyte-predominant Hodgkin lymphoma (nLPHL) is critical for incorporating PET into prospective trials. PET scans from Children's Oncology Group study...
3.
Marks L, Ritter V, Agrusa J, Agrusa J, Kamdar K, Rivers J, et al.
Blood Adv
. 2025 Jan;
9(6):1356-1365.
PMID: 39841960
Treatment options for patients with relapsed or refractory (R/R) anaplastic large cell lymphoma (ALCL) have increased in the era of targeted therapies such as brentuximab vedotin (BV) and anaplastic lymphoma...
4.
Dharnidharka V, Wylie K, Wylie T, Ruzinova M, Goss C, Storch G, et al.
Transplant Direct
. 2024 Oct;
10(11):e1723.
PMID: 39473523
Post-transplant lymphoproliferative disorders (PTLDs) remain a feared complication of transplantation, with significant morbidity and mortality. The oncogenic Epstein-Barr virus (EBV) is a key pathogenic driver in 50%-80% of cases. Numerous...
5.
Dharnidharka V, Ruzinova M, Marks L
Semin Nephrol
. 2024 Mar;
44(1):151503.
PMID: 38519279
Post-transplant lymphoproliferative disorders (PTLDs) are a heterogenous set of unregulated lymphoid cell proliferations after organ or tissue transplant. A majority of cases are associated with the Epstein-Barr virus and higher...
6.
Alig S, Shahrokh Esfahani M, Garofalo A, Li M, Rossi C, Flerlage T, et al.
Nature
. 2023 Dec;
625(7996):778-787.
PMID: 38081297
The scarcity of malignant Hodgkin and Reed-Sternberg cells hampers tissue-based comprehensive genomic profiling of classic Hodgkin lymphoma (cHL). By contrast, liquid biopsies show promise for molecular profiling of cHL due...
7.
Feraco A, Zhou Y, Zheng Y, Marks L, Friedmann A, Weinstein H, et al.
Blood Adv
. 2023 Aug;
7(21):6665-6667.
PMID: 37647596
No abstract available.
8.
Chu Y, Gardenswartz A, Diorio C, Marks L, Lowe E, Teachey D, et al.
Best Pract Res Clin Haematol
. 2023 Mar;
36(1):101442.
PMID: 36907635
The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately...
9.
Forlenza C, Rosenzweig J, Mauguen A, Buhtoiarov I, Cuglievan B, Dave H, et al.
Blood Adv
. 2023 Mar;
7(13):3225-3231.
PMID: 36897253
Outcomes for children and adolescents with relapsed and refractory Hodgkin lymphoma (HL) are poor, with ∼50% of patients experiencing a subsequent relapse. The anti-CD30 antibody-drug conjugate brentuximab vedotin improved progression-free...
10.
Afify Z, Taj M, Orjuela-Grimm M, Srivatsa K, Miller T, Edington H, et al.
Cancer
. 2022 Dec;
129(5):780-789.
PMID: 36571557
Background: Pediatric Epstein-Barr virus-negative monomorphic post solid organ transplant lymphoproliferative disorder [EBV(-)M-PTLD] comprises approximately 10% of M-PTLD. No large multi-institutional pediatric-specific reports on treatment and outcome are available. Methods: A...